Cigna (CI) is rated a 'Strong Buy' due to its attractive valuation at a forward P/E of 8.9x, strong Q2 2026 earnings, and raised full-year EPS guidance. The company targets 10-14% annual EPS growth through 2030, driven by advancements in AI and specialty pharmacy. Its asset-light business model, expanding specialty pharma presence, and aggressive share buybacks support a potential high-teens total annual return. This makes Cigna a compelling choice for investors seeking growth and value in the healthcare sector.
Cigna (CI) trades at USD 273.01 on Pluang as of Oct 01, 2026 19:31 WIB, showing a modest 0.43% gain for the day. The stock remains below its 52-week high of USD 311.00 but comfortably above the 52-week low of USD 244.41, indicating a mid-range position within its annual price movement. With a market cap of $71.83 billion and a dividend yield of 2.3%, Cigna attracts full buy interest from Pluang users, reflecting confidence in its growth prospects.
